The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | ALLO-715: novel allogenic CAR T-cell therapy in myeloma
Parameswaran Hari, MBBS, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the characteristics of ALLO-715, a targeted chimeric antigen receptor (CAR) T-cell therapy currently being assessed in the Phase I UNIVERSAL trial (NCT04093596). ALLO-715 is the first allogenic off-the-shelf donor-derived B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy for patients with multiple myeloma. Dr Hari additionally explains potential complications of donor-derived T-cells, such as graft-versus-host disease (GvHD), as well as mitigation strategies, such as administration of ALLO-647 as part of the lymphodepletion regimen. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
